LCN2 and chronic kidney disease: Diagnostic innovations include microfluidic biosensors for non-invasive, high-sensitivity detection of CKD biomarkers such as albumin and neutrophil gelatinase-associated lipocalin (NGAL), as well as multiplex platforms that analyze multiple analytes in urine or blood simultaneously.